BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/16/2025 5:36:38 AM | Browse: 112 | Download: 463
 |
Received |
|
2024-08-26 03:10 |
|
Peer-Review Started |
|
2024-09-05 01:12 |
|
First Decision by Editorial Office Director |
|
2025-01-08 12:26 |
|
Return for Revision |
|
2025-01-08 12:26 |
|
Revised |
|
2025-01-18 04:03 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-02-05 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-06 08:54 |
|
Articles in Press |
|
2025-02-06 08:54 |
|
Edit the Manuscript by Language Editor |
|
2025-02-08 03:21 |
|
Typeset the Manuscript |
|
2025-02-12 09:58 |
|
Publish the Manuscript Online |
|
2025-04-16 05:36 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
MicroRNA-155 modulation by renin-angiotensin system inhibitors may underlie their enigmatic role in COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Konstantinos I Papadopoulos, Alexandra Papadopoulou and Tar Choon Aw |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Konstantinos I Papadopoulos, Chief Physician, MD, PhD, Department of R and D, THAI StemLife, 566/3 THAI StemLife Bldg., Soi Ramkhamhaeng 39 (Thepleela 1), Prachaouthit Road, Wangthonglang, Bangkok 10310, Thailand. kostas@thaistemlife.co.th |
| Key Words |
Angiotensin converting enzyme inhibitors; Angiotensin II type 1 receptor blocker; COVID-19; MicroRNA; Mineralocorticosteroid receptor antagonists; MicroRNA-155; Renin-angiotensin system inhibitors; SARS-CoV-2; Sodium-glucose transporter 2 |
| Core Tip |
The role of renin-angiotensin system (RAS) inhibition in coronavirus disease 2019 (COVID-19) remains enigmatic. Novel insights involving interference of microRNA-155 (miR-155) and erythropoietin (EPO) levels support a detrimental role by RAS inhibitors in the elderly and in co-morbidities. Current pharmacological interventions in COVID-19 employing RAS inhibition should consider these complex but potentially detrimental miR-155 effects. Future research should address the knowledge gap on how RAS inhibition affects miR-155 while therapeutic strategies should focus on pharmacological interventions that restore EPO and miR-155 levels and functionality. The use of tissue specific miRNA-analogs could become a reality by then. |
| Publish Date |
2025-04-16 05:36 |
| Citation |
Papadopoulos KI, Papadopoulou A, Aw TC. MicroRNA-155 modulation by renin-angiotensin system inhibitors may underlie their enigmatic role in COVID-19. World J Exp Med 2025; 15(2): 100748 |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i2/100748.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i2.100748 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
